Market Overview

Baird Downgrades Express Scripts On Industry Instability

Share:
Baird Downgrades Express Scripts On Industry Instability

Regulatory uncertainty is rising too high for Baird Equity Research to remain bullish on Express Scripts Holding Co (NASDAQ: ESRX).

The Rating

Analyst Eric Coldwell downgraded Express Scripts to Neutral with an $81 price target.

The Thesis

Previously, Express Scripts’ improving new business trends, its consistency in core profit and loss statements and a better sentiment for pharmacy benefits managers (PBMs) made for an attractive near-term risk-reward profile.

Now, however, Coldwell considers upside dependent on a successful sale to CIGNA Corporation (NYSE: CI). The deal is seen to have favorable odds, but the risk of downside has “significantly increased.”

“PBMs have been under heavy political attack in recent weeks and the stand-alone trajectory is almost impossible to model right now,” Coldwell wrote in a note.

The risk is primarily in recent advancement of plans for rebate-model reform.

“[It] could be material to ESRX profit model and makes long-term stand-alone modeling almost impossible right now,” Coldwell wrote.

Price Action

At time of publication, shares were trading up marginally around $77.

Related Links:

CVS: An Interesting Trade On The Cigna-Express Scripts Deal

Predicted Gross Margin Pressure, EPS Erosion Turn Bernstein Bearish On Express Scripts

Latest Ratings for ESRX

DateFirmActionFromTo
Nov 2018MaintainsMarket PerformMarket Perform
Nov 2018MaintainsEqual-WeightEqual-Weight
Sep 2018DowngradesOutperformNeutral

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: Baird Equity Research Eric ColdwellAnalyst Color Downgrades Analyst Ratings Best of Benzinga

 

Related Articles (ESRX + CI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com